Protagonist Therapeutics Inc (NASDAQ:PTGX) – Stock analysts at Leerink Swann issued their Q1 2018 earnings per share (EPS) estimates for Protagonist Therapeutics in a report issued on Thursday. Leerink Swann analyst J. Schwartz expects that the company will earn ($0.13) per share for the quarter. Leerink Swann also issued estimates for Protagonist Therapeutics’ Q2 2018 earnings at ($0.27) EPS, Q3 2018 earnings at ($0.52) EPS, Q4 2018 earnings at $0.29 EPS, FY2018 earnings at ($0.61) EPS and FY2019 earnings at ($1.54) EPS.
Several other brokerages also recently issued reports on PTGX. Zacks Investment Research downgraded Protagonist Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 4th. BidaskClub raised Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 3rd. BMO Capital Markets reaffirmed an “outperform” rating and issued a $42.00 price target (down from $44.00) on shares of Protagonist Therapeutics in a research report on Thursday, March 8th. Finally, Stifel Nicolaus began coverage on Protagonist Therapeutics in a research report on Monday, January 29th. They issued a “buy” rating and a $32.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $34.00.
Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings results on Wednesday, March 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.19. The business had revenue of $11.28 million during the quarter, compared to analyst estimates of $8.75 million.
In related news, insider David Y. Liu sold 3,500 shares of Protagonist Therapeutics stock in a transaction dated Monday, March 12th. The stock was sold at an average price of $21.29, for a total transaction of $74,515.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Dinesh V. Ph D. Patel sold 1,790 shares of Protagonist Therapeutics stock in a transaction dated Wednesday, December 20th. The stock was sold at an average price of $19.55, for a total value of $34,994.50. Following the sale, the insider now directly owns 192,227 shares in the company, valued at $3,758,037.85. The disclosure for this sale can be found here. Over the last three months, insiders have sold 19,444 shares of company stock worth $394,354. 15.50% of the stock is owned by company insiders.
A number of hedge funds have recently added to or reduced their stakes in PTGX. Teachers Advisors LLC grew its position in Protagonist Therapeutics by 71.4% during the second quarter. Teachers Advisors LLC now owns 16,218 shares of the company’s stock worth $183,000 after buying an additional 6,757 shares in the last quarter. TIAA CREF Investment Management LLC grew its position in Protagonist Therapeutics by 19.5% during the second quarter. TIAA CREF Investment Management LLC now owns 23,372 shares of the company’s stock worth $264,000 after buying an additional 3,812 shares in the last quarter. Northern Trust Corp grew its position in Protagonist Therapeutics by 24.0% during the second quarter. Northern Trust Corp now owns 98,825 shares of the company’s stock worth $1,118,000 after buying an additional 19,159 shares in the last quarter. Vanguard Group Inc. grew its position in Protagonist Therapeutics by 3.8% during the second quarter. Vanguard Group Inc. now owns 325,395 shares of the company’s stock worth $3,680,000 after buying an additional 11,881 shares in the last quarter. Finally, State Street Corp grew its position in Protagonist Therapeutics by 20.9% during the second quarter. State Street Corp now owns 112,474 shares of the company’s stock worth $1,270,000 after buying an additional 19,411 shares in the last quarter. 57.77% of the stock is currently owned by institutional investors and hedge funds.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.